FDA fast tracks PHST001 as treatment for ovarian cancer
Pheast Therapeutics has received fast track designation from the U.S. Food and Drug Administration (FDA) for PHST001, its candidate treatment for ovarian cancer, a type…
Gynecological cancer
Pembrolizumab improves survival outcomes in ovarian cancer trial
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…
Testosterone in gender-affirming care doesn’t raise cancer risk
The use of testosterone as part of gender-affirming care does not increase the risk of gynecological cancers in transgender men or gender-diverse people, a study…
World Ovarian Cancer Day to be observed May 8
Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.
Tepylute for breast, ovarian cancer launched in US
Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the…
Provider genetic testing may raise gynecological cancer testing rates
Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with gynecological cancers who underwent testing. That’s…
Ovarian cancer immunotherapy reactivates immune cells: Study
An experimental immunotherapy known as MOv18 IgE showed promise in overcoming the immune suppression caused by ovarian cancer cells, potentially enabling the immune system…
Trial to test relacorilant combo in platinum-resistant ovarian cancer
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with…
Trial: Relacorilant aids survival in platinum-resistant ovarian cancer
Adding relacorilant to standard chemotherapy was shown to extend survival among people with platinum-resistant ovarian cancer, meeting the primary endpoint, or goal, of a…
Nemvaleukin plus Keytruda fails in Phase 3 trial in ovarian cancer
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
